{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:55:28Z","timestamp":1791590128591,"version":"4.3.4"},"reference-count":69,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Zielsetzung Ziel dieser Zusammenfassung ist das Vermitteln einer \u00dcbersicht zu den verschiedenen Ansatzpunkten, Wirkmechanismen und Indikationen diverser Biologika, die bei der\n\t\t\t\t\tTherapie der nichtinfekti\u00f6sen Uveitis zum Einsatz kommen.<\/jats:p><jats:p>\n          Material und Methoden Etablierte sowie aktuelle Literatur wurden herangezogen, um die biochemischen und pathophysiologischen Grundlagen sowie eine evidenzbasierte Empfehlung zum\n\t\t\t\t\tTherapieeinsatz verschiedener Biologika bei nichtinfekti\u00f6ser Uveitis allgemein und bei speziellen Uveitisentit\u00e4ten darzulegen.<\/jats:p><jats:p>\n          Ergebnisse F\u00fcr viele Biologika, hier nennenswert TNF-\u03b1-Inhibitoren, einige Interleukininhibitoren, Interferone sowie B-\u00a0und T-Zell-Inhibitoren, liegen mittlerweile gute Daten vor,\n\t\t\t\t\twas ihren Einsatz in der Uveitistherapie mehr als rechtfertigt. Dies trifft insbesondere f\u00fcr den TNF-\u03b1-Inhibitor Adalimumab zu, welcher der einzig zugelassene Vertreter f\u00fcr diese Indikation\n\t\t\t\t\tunter den vorgestellten Biologika ist.<\/jats:p><jats:p>\n          Schlussfolgerungen Die Biologika haben die Behandlung der Uveitis revolutioniert und sind aus der aktuellen Therapie der intraokularen Entz\u00fcndung nicht mehr wegzudenken. Biologika\n\t\t\t\t\twerden bei Ineffektivit\u00e4t oder Unvertr\u00e4glichkeit konventioneller immunsuppressiver Medikamente empfohlen, aber auch bei der Therapie von schwerwiegenden Uveitisformen (z.\u200aB. Morbus Beh\u00e7et).\n\t\t\t\t\tDie TNF-\u03b1-Inhibitoren sind die am h\u00e4ufigsten verwendeten Biologika bei Uveitis.<\/jats:p>","DOI":"10.1055\/a-1737-4425","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:41:35Z","timestamp":1649983295000},"page":"686-694","source":"Crossref","is-referenced-by-count":3,"title":["Therapie der Uveitis mit Biologika"],"prefix":"10.1055","volume":"239","author":[{"given":"Vita Louisa Sophie","family":"Dingerkus","sequence":"additional","affiliation":[{"name":"Department f\u00fcr Augenheilkunde, Stadtspital Z\u00fcrich, Z\u00fcrich, Schweiz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias Dieter","family":"Becker","sequence":"additional","affiliation":[{"name":"Department f\u00fcr Augenheilkunde, Stadtspital Z\u00fcrich, Z\u00fcrich, Schweiz"},{"name":"Department f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Heidelberg, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshka","family":"Doycheva","sequence":"additional","affiliation":[{"name":"Department f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum T\u00fcbingen, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"ref3","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.4103\/ijo.IJO_564_20","article-title":"Interleukins and cytokine biomarkers in uveitis","volume":"68","author":"S Balamurugan","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"T Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.smim.2013.12.004","article-title":"Inhibition of IL-6 family cytokines by SOCS3","volume":"26","author":"J J Babon","year":"2014","journal-title":"Semin Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ejcb.2011.09.010","article-title":"Interleukin-6 signalling: more than Jaks and STATs","volume":"91","author":"R Eulenfeld","year":"2012","journal-title":"Eur J Cell Biol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1167\/iovs.16-19758","article-title":"The Cytokine Interleukin-6 and the Chemokines CCL20 and CXCL13 Are Novel Biomarkers of Specific Endogenous Uveitic Entities","volume":"57","author":"A M Abu El-Asrar","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2174\/1566524015666150731100012","article-title":"Cytokine Expression Profile in Aqueous Humor and Sera of Patients with Acute Anterior Uveitis","volume":"15","author":"W Chen","year":"2015","journal-title":"Curr Mol Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1167\/iovs.16-20799","article-title":"Cytokines and Chemokines Involved in Acute Retinal Necrosis","volume":"58","author":"L de Visser","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/rheumatology\/ken489","article-title":"Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis","volume":"48","author":"T Yoshimura","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/ICU.0000000000000466","article-title":"Cytokines in uveitis","volume":"29","author":"J E Weinstein","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ajo.2011.01.031","article-title":"Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy","volume":"152","author":"J J Kuiper","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","article-title":"Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis","volume":"139","author":"A M El-Asrar","year":"2011","journal-title":"Clin Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3109\/09273948.2013.815786","article-title":"Elevated serum levels of interleukin-17A in\u00a0uveitis patients","volume":"21","author":"S Jawad","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"ref15","first-page":"32","article-title":"Up-regulation of Th17 and related cytokines in Behcet\u02bcs disease corresponding to disease activity","volume":"31","author":"S Y Na","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1006\/jaut.1998.0197","article-title":"Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis","volume":"11","author":"A D Dick","year":"1998","journal-title":"J Autoimmun"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.4049\/jimmunol.0901340","article-title":"TNFR1-dependent regulation of myeloid cell function in experimental autoimmune uveoretinitis","volume":"183","author":"B J Raveney","year":"2009","journal-title":"J Immunol"},{"key":"ref18","first-page":"2003","article-title":"Intraocular and serum cytokine profiles in patients with intermediate uveitis","volume":"17","author":"N V Valentincic","year":"2011","journal-title":"Mol Vis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1006\/mvre.1995.1024","article-title":"Interferon-alpha 2b enhances barrier function of bovine retinal microvascular endothelium in vitro","volume":"49","author":"M C Gillies","year":"1995","journal-title":"Microvasc Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in Patients with Active Noninfectious Uveitis","volume":"375","author":"G J Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised,\n\t\t\t\t\tplacebo-controlled phase 3 trial","volume":"388","author":"Q D Nguyen","year":"2016","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III","volume":"125","author":"E B Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1745-6215-15-14","article-title":"A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis\n\t\t\t\t\tassociated uveitis (SYCAMORE Trial)","volume":"15","author":"A V Ramanan","year":"2014","journal-title":"Trials"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","volume":"77","author":"P Quartier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/bjophthalmol-2012-302292","article-title":"Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial","volume":"97","author":"E B Suhler","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients","volume":"119","author":"M D\u00edaz-Llopis","year":"2012","journal-title":"Ophthalmology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"M Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.3899\/jrheum.131289","article-title":"Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis","volume":"41","author":"J C van Denderen","year":"2014","journal-title":"J Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"D van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and\n\t\t\t\t\tNonradiographic Axial Spondyloarthritis","volume":"68","author":"M M Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"L Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/art.40391","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis\/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures\n\t\t\t\t\tand Treatment Targets in Psoriatic Arthritis","volume":"70","author":"L C Coates","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/sj.eye.6702352","article-title":"Adalimumab for sight-threatening uveitis in Behcet\u02bcs disease","volume":"21","author":"B Mushtaq","year":"2007","journal-title":"Eye (Lond)"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/09273948.2010.483314","article-title":"Clinical experience with adalimumab in the treatment of ocular Behcet disease","volume":"18","author":"A Bawazeer","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"G Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3109\/09273948.2011.633205","article-title":"Infliximab and adalimumab for uveitis","volume":"20","author":"J N Martel","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network","volume":"68","author":"H Vallet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"E B Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/bjo.2009.168856","article-title":"Timing of recurrent uveitis in patients with Behcet\u02bcs disease receiving infliximab treatment","volume":"95","author":"Y Yamada","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","article-title":"Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet\u02bcs disease: a multicenter study","volume":"121","author":"M Takeuchi","year":"2014","journal-title":"Ophthalmology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1001\/archophthalmol.2009.141","article-title":"Infliximab therapy for refractory uveitis: 2-year results of a prospective trial","volume":"127","author":"E B Suhler","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative","volume":"125","author":"A D Dick","year":"2018","journal-title":"Ophthalmology"},{"key":"ref43","first-page":"680","article-title":"Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis","volume":"37","author":"G M Tosi","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.55563\/clinexprheumatol\/j9ysbm","article-title":"Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy","volume":"39","author":"D Prieto-Pena","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","article-title":"Immunogenicity of TNF-Inhibitors","volume":"11","author":"S Atiqi","year":"2020","journal-title":"Front Immunol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet\u02bcs disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"C Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3899\/jrheum.160064","article-title":"Canakinumab for Childhood Sight-threatening Refractory Uveitis: A Case Series","volume":"43","author":"A Brambilla","year":"2016","journal-title":"J Rheumatol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of Gevokizumab in Patients with Behcet\u02bcs Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study","volume":"26","author":"I Tugal-Tutkun","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"ref49","first-page":"S75","article-title":"Tocilizumab in severe and refractory non-infectious uveitis","volume":"32 (4 Suppl.\u200984)","author":"M Papo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.autrev.2017.08.002","article-title":"Targeting interleukin-6 in autoimmune uveitis","volume":"16","author":"M Mesquida","year":"2017","journal-title":"Autoimmun Rev"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3109\/09273948.2015.1099680","article-title":"Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment","volume":"25","author":"C ME Deuter","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1097\/IAE.0000000000001690","article-title":"Twenty-Four Month Follow-up of Tocilizumab Therapy for Refractory Uveitis-Related Macular Edema","volume":"38","author":"M Mesquida","year":"2018","journal-title":"Retina"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis","volume":"183","author":"Y J Sepah","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five\n\t\t\t\t\tPatients","volume":"69","author":"V Calvo-Rio","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behcet\u02bcs disease: multicentre retrospective study","volume":"57","author":"B Atienza-Mateo","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"A D Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","volume":"122","author":"E Letko","year":"2015","journal-title":"Ophthalmology"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/ceo.13922","article-title":"Secukinumab in HLA-B27 associated uveitis","volume":"49","author":"E Miserocchi","year":"2021","journal-title":"Clin Exp Ophthalmol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","article-title":"Rituximab therapy for refractory scleritis: results of a phase I\/II dose-ranging, randomized, clinical trial","volume":"121","author":"E B Suhler","year":"2014","journal-title":"Ophthalmology"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000486791","article-title":"Cyclophosphamide or Rituximab Treatment of Scleritis and Uveitis for Patients with Granulomatosis with Polyangiitis","volume":"61","author":"A Ahmed","year":"2019","journal-title":"Ophthalmic Res"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/bjophthalmol-2015-306790","article-title":"Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis","volume":"100","author":"E Miserocchi","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet\u02bcs disease; randomized single-blind control study (pilot study)","volume":"13","author":"F Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3899\/jrheum.140410","article-title":"Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis","volume":"42","author":"C Tappeiner","year":"2015","journal-title":"J Rheumatol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000336324","article-title":"Interferon-alpha therapy in noninfectious uveitis","volume":"51","author":"C Deuter","year":"2012","journal-title":"Dev Ophthalmol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon alfa-2a for the treatment of Behcet\u02bcs disease with sight threatening posterior or panuveitis","volume":"87","author":"I Kotter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet\u02bcs disease","volume":"62","author":"C M Deuter","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1136\/bjo.2008.153874","article-title":"Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis","volume":"93","author":"C M Deuter","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/09273948.2019.1585883","article-title":"Interferon Alpha for Refractory Pseudophakic Cystoid Macular Edema (Irvine-Gass Syndrome)","volume":"28","author":"S Dimopoulos","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3109\/09273948.2011.562341","article-title":"Successful treatment of chronic pseudophakic macular edema (Irvine-Gass syndrome) with interferon alpha: a report of three cases","volume":"19","author":"C M Deuter","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/bjo.2004.061119","article-title":"Interferon as a treatment for uveitis associated with multiple sclerosis","volume":"89","author":"M D Becker","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ajo.2013.05.002","article-title":"Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial","volume":"156","author":"F Mackensen","year":"2013","journal-title":"Am J Ophthalmol"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1737-4425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T22:44:09Z","timestamp":1652222649000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1737-4425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":69,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2022,5,10]]},"published-print":{"date-parts":[[2022,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1737-4425","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]}}}